Paul joined NEA in 2008. He focuses on later-stage biotechnology and life sciences investments. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst designation. He board observer of Sunesis and Interleukin Genetics, a former board member of TESARO (NASDAQ: TRSO), and manages a number of NEA’s other late-stage and public investments.